Innovations in Hearing Accessibility and Technology (IHAT) Study
Launched by UNIVERSITY OF COLORADO, DENVER · Nov 13, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The IHAT Study is looking at how different ways of providing over-the-counter (OTC) hearing aids compare to prescription hearing aids fitted by specialists. This research focuses on adults with mild to moderate hearing loss, examining how each type of hearing aid affects people's everyday experiences, thinking skills, and even brain activity related to hearing. The study also aims to understand what types of people prefer OTC or prescription hearing aids, what influences their choices, and the costs associated with different service options. This information will help improve hearing aid access and support healthcare providers and policymakers in making informed decisions.
To participate in the study, you need to be at least 40 years old, have mild to moderate hearing loss, and be able to read and understand patient materials. You should also be willing to be assigned randomly to one of the four groups in the study and own a smartphone. If you have severe hearing loss, certain ear conditions, or specific neurological issues, you may not qualify. The study is currently recruiting participants, and it's a great opportunity to contribute to valuable research that can lead to better hearing solutions for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult onset, bilateral, mild-to-moderate sensorineural hearing loss documented by audiological evaluation
- • Aged 40 years or older
- • No previous HA experience greater than 3 months
- • Able to read and understand patient education materials
- • Willing to be randomized to one of the four groups, and
- • Owns a smartphone
- Exclusion Criteria:
- • Hearing loss that is too severe for OTC HAs
- • Middle ear disorders or conductive pathology present
- • Asymmetrical hearing loss
- • Diagnosed neurological condition such as dementia or Parkinson's disease or a score lower than 25 on the MOCA
- • Non-English speaking as it may impact the ability to complete our test battery
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Boulder, Colorado, United States
Patients applied
Trial Officials
Vinaya Manchaiah, AuD, MBA, PhD
Principal Investigator
University of Colorado, Denver
Anu Sharma, PhD
Principal Investigator
University of Colorado, Boulder
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported